Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug ... and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

also known as Tanabe Pharma, is the pharmaceutical division of Mitsubishi Chemical Group. Under deal terms announced Friday, this pharma unit, which traces its origins to a Japanese business ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI spun off its Zeneca drug business. In Japan, many major chemical ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth ... investment in its core chemicals business as well as to help it reduce ...

The Boston private equity firm said the deal followed several recent initiatives by the Japanese government and regulators to “accelerate the development and approval of innovative medicines.” ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $ ... said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen ...